bioAffinity Technologies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

bioAffinity Technologies şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-10.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-10.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: BIAF şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: BIAF şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

bioAffinity Technologies Piyasaya Karşı Temettü Getirisi

BIAF temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (BIAF)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (BIAF) (3 yıla kadar)	n/a

Önemli Temettü: BIAF şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, BIAF şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: BIAF şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: BIAF herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

bioAffinity Technologies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. Announces Executive Changes

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.662782 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $2.662782 million.

bioAffinity Technologies, Inc. Appoints J. Michael Edwards as Chief Financial Officer

New major risk - Share price stability

bioAffinity Technologies, Inc. Announces Chief Financial Officer Changes

bioAffinity Technologies, Inc. Announces Chief Financial Officer Changes

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

bioAffinity Technologies, Inc. announced that it has received $1.302084 million in funding

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.45 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $0.45 million.

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $0.45 million.

New major risk - Share price stability

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2023)

bioAffinity Technologies, Inc., Annual General Meeting, Jun 04, 2024

Full year 2023 earnings released: US$0.91 loss per share (vs US$1.81 loss in FY 2022)

bioAffinity Technologies, Inc. announced that it has received $2.624 million in funding

bioAffinity Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

New major risk - Share price stability

bioAffinity Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million.

bioAffinity Technologies, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

bioAffinity Technologies, Inc. Appoints Sandeep Bansal to Medical and Scientific Advisory Board

bioAffinity Technologies, Inc. Appoints Jamie Platt, Ph.D., to its Board of Directors

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$1.17 loss in 3Q 2022)

bioAffinity Technologies, Inc. Provides Earnings Guidance for the Year 2023 and for the Next 12 Months(fourth quarter 2023 to third quarter 2024)

bioAffinity Technologies, Inc. Appoints Dallas J. Coleman as National Director of Sales

New major risk - Share price stability

bioAffinity Technologies, Inc. Announces Board Changes

New major risk - Financial position

AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer

bioAffinity Technologies, Inc. Appoints Julie Anne Overton as Director of Corporate Communications

bioAffinity Technologies, Inc. Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

Bioaffinity Technologies Announces Notice to Award U.S. Patent and Trademark Office Protecting Novel Compounds for Specific Delivery of Cancer Treatments

Bioaffinity Technologies Announces Joining of Sheila Habib and David Hill to Scientific and Medical Advisory Board

bioAffinity Technologies, Inc. Announces the People’S Republic of China Awarded Certificate of Patent to Company’S Wholly Owned Subsidiary Oncoselect® for Patent “Porphyrin Compounds and Compositions Useful for Treating Cancer”

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference

bioAffinity Technologies receives ~$7.7M from exercise of warrants

BioAffinity stock jumps 42% after peer-reviewed data on lung test

bioAffinity Technologies, Inc. has completed an IPO in the amount of $8.033281 million.

bioAffinity Technologies, Inc. has completed an IPO in the amount of $8.033281 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin